Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...
H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. The company has strong ...
Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 ...
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find ...
Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...
January 05, 2025, 00:04 am ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...